Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
The Human Microbiome in Early Life: Implications to Health and Disease presents recent research advances that have highlighted the significance of early life, possibly beginning before birth, in the establishment of both the microbiome and its role in health and disease. The book reviews current knowledge on the origins of the human microbiota in early life, presents exposures which may disturb normal microbial colonization, and covers their implications to the risk of disease. Finally, emerging means to modify the early human microbiome to improve health are discussed.
- Examines the timeline of the human microbiome, from before conception to infancy, with an emphasis on clinical implications
- Evaluates the effort to understand not only the composition but also the origin of the microbiome
- Proves the emerging means to modify the human microbiome and particularly ‘the first 1000 days of life’ improve human health and prevent disease
- Generates resources to facilitate characterization of the human microbiota to further our understanding of how the microbiome impacts human health and disease
Academia: microbiology, nutrition, public health, medicine. Industry: dairy, pharmaceuticals, nutrition. Clinic: OB/GYN, paediatrics, dieticians
Section I. Pregnancy and Fetal Life
1. Microbiome During Healthy Pregnancy
2. Microbiome and Complications of Pregnancy
3. Microbial Signatures of Preterm Birth
4. Prenatal Origins of the Infant Gut Microbiome
Section II. Birth - Entering the World Dominated by Microbes
5. Mode of Delivery, the Infant Microbiome and Risk of Disease
6. Intrapartum and Neonatal Antibiotic Exposure
7. Preterm Infants - Gut Microbiome and Complications of Prematurity
Section III. Infancy - Establishment of the Microbiome and Healthy Development
8. The Compositional Development of the Microbiome in Early Life
9. Microbes, Human Milk, and Prebiotics
10. The Early Gut Microbiome and the Risk of Chronic Disease
Section IV. Modifying Early Microbial Contact
11. Postbiotics: Defining the impact of inactivated microbes and their metabolites on promotion of health
12. Modification of the gut microbiota in attempt to reduce the risk of child disease - clinical data from prenatal interventions
13. Clinical Data from Postnatal Interventions
- No. of pages:
- © Academic Press 2021
- 1st September 2020
- Academic Press
- Paperback ISBN:
Dr. Koren received his PhD from Tel Aviv University and moved on to a postdoc at Cornell University where he was part of the NIH Human Microbiome Project. Currently, Dr. Koren is head of the Koren Lab. His research focuses on the microbiome, studying the roles of the trillions of bacteria that reside within each individual. They have a wide variety of research interests including interactions between microbiota and the host in health and in disease states in general and specific interest in the microbiome of pregnancy and infancy.
Koren Lab, Azrieli Faculty of Medicine, Bar Ilan University, Israel
Dr. Samuli Rautava received his MD and PhD in pediatrics from the University of Turku, Finland. After completing a postdoctoral fellowship at the Mucosal Immunology and Biology Research Center at Harvard Medical School and the Massachusetts General Hospital for Children, Dr. Rautava continued his clinical training at the University of Turku and Turku University Hospital, earning specialist degrees in pediatrics and neonatology. He then completed a fellowship at the Hospital for Sick Children in Toronto, Ontario, where he was presented with the Sick Kids Fellow of the Year Award. Currently, Dr. Rautava works as the Head of Neonatology at Helsinki University Hospital and Assistant Professor of Neonatology at the University of Helsinki in Finlandas well as Adjunct Professor of Experimental Pediatrics at the University of Turku. Dr. Rautava’s research efforts focus on the short- and long-term health effects of early microbial contact and the transfer of bacteria from the mother to the infant during fetal life, delivery, and early infancy. Specific areas of interest include the causes of spontaneous preterm birth and the impact of early antibiotic use on infant gut microbiota development and later health. Dr. Rautava conducts clinical trials using probiotics in pregnant and breastfeeding women and preterm infants, complemented with experimental studies in close collaboration with experts in microbiology, immunology, and epigenetics.
Head of Department of Neonatology, Helsinki University Hospital, Helsinki, Finland; Assistant Professor of Neonatology, University of Helsinki, Helsinki, Finland; Adjunct Professor of Experimental Pediatrics, University of Turku, Turku, Finland
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.